These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25648563)

  • 41. Pharmacophore modeling using site-identification by ligand competitive saturation (SILCS) with multiple probe molecules.
    Yu W; Lakkaraju SK; Raman EP; Fang L; MacKerell AD
    J Chem Inf Model; 2015 Feb; 55(2):407-20. PubMed ID: 25622696
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacophore modeling and three-dimensional database searching for drug design using catalyst.
    Kurogi Y; Güner OF
    Curr Med Chem; 2001 Jul; 8(9):1035-55. PubMed ID: 11472240
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An integrated platform for intuitive mathematical programming modeling using LaTeX.
    Triantafyllidis CP; Papageorgiou LG
    PeerJ Comput Sci; 2018; 4():e161. PubMed ID: 33816814
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Computational Approaches for the Design of Mosquito Repellent Chemicals.
    Basak SC; Bhattacharjee AK
    Curr Med Chem; 2020; 27(1):32-41. PubMed ID: 30378480
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Common Hits Approach: Combining Pharmacophore Modeling and Molecular Dynamics Simulations.
    Wieder M; Garon A; Perricone U; Boresch S; Seidel T; Almerico AM; Langer T
    J Chem Inf Model; 2017 Feb; 57(2):365-385. PubMed ID: 28072524
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combating Diseases with Computational Strategies Used for Drug Design and Discovery.
    Makhouri FR; Ghasemi JB
    Curr Top Med Chem; 2018; 18(32):2743-2773. PubMed ID: 30663568
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative validated molecular modeling of p53-HDM2 inhibitors as antiproliferative agents.
    Mondal C; Halder AK; Adhikari N; Saha A; Saha KD; Gayen S; Jha T
    Eur J Med Chem; 2015 Jan; 90():860-75. PubMed ID: 25535952
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fuzzy tricentric pharmacophore fingerprints. 1. Topological fuzzy pharmacophore triplets and adapted molecular similarity scoring schemes.
    Bonachéra F; Parent B; Barbosa F; Froloff N; Horvath D
    J Chem Inf Model; 2006; 46(6):2457-77. PubMed ID: 17125187
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proposing novel TNFα direct inhibitor Scaffolds using fragment-docking based e-pharmacophore modeling and binary QSAR-based virtual screening protocols pipeline.
    Zaka M; Abbasi BH; Durdagi S
    J Mol Graph Model; 2018 Oct; 85():111-121. PubMed ID: 30149308
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Structure versus function-The impact of computational methods on the discovery of specific GPCR-ligands.
    Bermudez M; Wolber G
    Bioorg Med Chem; 2015 Jul; 23(14):3907-12. PubMed ID: 25828056
    [TBL] [Abstract][Full Text] [Related]  

  • 51. First universal pharmacophore model for hERG1 K
    Durdagi S; Erol I; Salmas RE; Patterson M; Noskov SY
    J Mol Graph Model; 2017 Jun; 74():153-170. PubMed ID: 28499268
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacophore modeling for ADME.
    Guner OF; Bowen JP
    Curr Top Med Chem; 2013; 13(11):1327-42. PubMed ID: 23675939
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of Essential 2D and 3D Chemical Features for Discovery of the Novel Tubulin Polymerization Inhibitors.
    Azimi F; Ghasemi JB; Saghaei L; Hassanzadeh F; Mahdavi M; Sadeghi-Aliabadi H; Scotti MT; Scotti L
    Curr Top Med Chem; 2019; 19(13):1092-1120. PubMed ID: 31109275
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structural insights of JAK2 inhibitors: pharmacophore modeling and ligand-based 3D-QSAR studies of pyrido-indole derivatives.
    Gade DR; Kunala P; Raavi D; Reddy PK; Prasad RV
    J Recept Signal Transduct Res; 2015 Apr; 35(2):189-201. PubMed ID: 25140764
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
    Halder AK; Saha A; Saha KD; Jha T
    J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative analysis of pharmacophore screening tools.
    Sanders MP; Barbosa AJ; Zarzycka B; Nicolaes GA; Klomp JP; de Vlieg J; Del Rio A
    J Chem Inf Model; 2012 Jun; 52(6):1607-20. PubMed ID: 22646988
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A three-dimensional model of the delta-opioid pharmacophore: comparative molecular modeling of peptide and nonpeptide ligands.
    Shenderovich MD; Liao S; Qian X; Hruby VJ
    Biopolymers; 2000 Jun; 53(7):565-80. PubMed ID: 10766952
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of new human epidermal growth factor receptor-2 (HER2) inhibitors for potential use as anticancer agents via ligand-based pharmacophore modeling.
    Zalloum H; Tayyem R; Irmaileh BA; Bustanji Y; Zihlif M; Mohammad M; Rjai TA; Mubarak MS
    J Mol Graph Model; 2015 Sep; 61():61-84. PubMed ID: 26188796
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Computer-Aided Drug Design Methods.
    Yu W; MacKerell AD
    Methods Mol Biol; 2017; 1520():85-106. PubMed ID: 27873247
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery of FIXa inhibitors by combination of pharmacophore modeling, molecular docking, and 3D-QSAR modeling.
    Li P; Peng J; Zhou Y; Li Y; Liu X; Wang L; Zuo Z
    J Recept Signal Transduct Res; 2018 Jun; 38(3):213-224. PubMed ID: 29724133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.